{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":9,"sponsored":0,"items":[{"id":"n_thfhjbb55dws23sd6s4q","seq":1502586,"kind":"article","title":"GE, Danaher, Fresenius, Enhertu: This Week in Healthcare","url":"https://healthcare-digital.com/news/ge-danaher-fresenius-enhertu-this-week-in-healthcare","published":"2026-10-03T08:40:51Z","seen":"2026-10-03T08:40:51Z","lang":"en","source":{"id":"healthcare-digital.com","name":"healthcare-digital.com","domain":"healthcare-digital.com"},"via":"gdelt-gkg-english","topics":["economy","science","health","education"],"entities":[{"id":"Q16831645","name":"Fresenius","type":"org"},{"id":"Q80109553","name":"trastuzumab deruxtecan","type":"org"}],"story":"st_thfhjbb55dws23sd6s4q","category":"economy-business","category_p":0.47,"category2":"science-technology","sentiment":"neutral","tone":0.39,"political":0.02},{"id":"n_vrmem5ckogv7gpcnaaaq","seq":1355074,"kind":"article","title":"프레제니우스, 바이오시밀러 승부수…맵사이언스 100% 품었다","title_en":"Fresenius, bio-similar showdown... MapScience acquired 100%","url":"https://www.medipana.com/news/articleView.html?idxno=418709","summary":"독일 헬스케어기업 프레제니우스가 바이오시밀러 자회사 mAbxience(맵사이언스)의 지분을 100% 확보했다. 바이오시밀러를 미래 성장사업으로 키우기 위해 연구개발부터 생산·상업화까지 직접 통제하는 사업구조를 구축한다. 프레제니우스는 mAbxience의 잔여 지분 45%를 최대 7억5000만유로에 인수하고 완전자회사로 전환했다고 1일(현지시간) 밝혔다. 프레제니우스는 2022년 mAbxience 지분 55%를 인수해 이미 연결 자회사로 편입했다. 이번에 기존 주주인 스페인 인시드(Insud) 그룹으로부터 나머지 지분을 사들이면서 4","published":"2026-10-02T12:28:11Z","seen":"2026-10-02T13:41:52Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q16831645","name":"Fresenius","type":"org"}],"story":"st_vrmem5ckogv7gpcnaaaq","category":"science-technology","category_p":0.51,"category2":"economy-business","sentiment":"positive","tone":0.58,"political":0.01},{"id":"n_tswjdeva3vjqhzjwwq5a","seq":1148321,"kind":"article","title":"Biosimilar-Markt: Fresenius kauft Biopharma-Tochter komplett","title_en":"Biosimilar market: Fresenius buys Biopharma subsidiary completely","url":"https://www.apotheke-adhoc.de/nachrichten/detail/markt/biosimilar-markt-fresenius-kauft-biopharma-tochter-komplett","summary":"Der Gesundheitskonzern Fresenius übernimmt seine Biopharma-Tochter mAbxience komplett und stärkt damit sein Geschäft mit Nachahmerarzneien. Für die übrigen Anteile im Umfang von 45 Prozent bezahlt der Dax-Konzern bis zu 750 Millionen Euro, wie er in Bad Homburg mitteilte. Verkäufer sind die Unternehmen Insud und Invim. Der Vertrag wurde den Angaben zufolge am Mittwoch unterschrieben und vollzogen. Behördliche Genehmigungen seien nicht nötig gewesen.Vom Kaufpreis stehen 50…","published":"2026-10-01T13:57:06Z","seen":"2026-10-01T13:57:06Z","lang":"de","country":"DE","source":{"id":"kite-apotheke-adhoc-de-8cd12d","name":"apotheke-adhoc.de","domain":"apotheke-adhoc.de"},"via":"kite-apotheke-adhoc-de-8cd12d","topics":["healthcare","germany"],"entities":[{"id":"Q16831645","name":"Fresenius","type":"org"},{"id":"Q115868919","name":"Biopharma","type":"org"}],"image":"https://www.apotheke-adhoc.de/fileadmin/user_upload_archive/content/redaktion/Fotos_Typo3/Bildergalerien/Fresenius/fresenius-zentrale-schild-aa.jpg","story":"st_phj4muukmesa6mdsanuq","category":"economy-business","category_p":0.8,"sentiment":"positive","tone":0.34,"political":0.02},{"id":"n_juqddwnu5ge3xrerzz2a","seq":1109623,"kind":"article","title":"Fresenius schluckt Biopharma-Tochter mAbxience komplett","url":"https://www.aerzteblatt.de/news/fresenius-schluckt-biopharma-tochter-mabxience-komplett-ac5300e4-ad44-4efc-832f-731156582a7c","summary":"Bad Homburg – Der Gesundheitskonzern Fresenius übernimmt seine Biopharma-Tochter mAbxience komplett. Für die übrigen Anteile im Umfang von 45 Prozent bezahlt der Dax-Konzern bis zu 750 Millionen Euro, wie er in Bad Homburg mitteilte. Verkäufer sind die Unternehmen Insud und Invim. Der Vertrag wurde den Angaben zufolge gestern unterschrieben und... [weiter lesen]","published":"2026-10-01T10:13:04Z","seen":"2026-10-01T10:15:42Z","lang":"en","source":{"id":"kite-aerzteblatt-de-f25596","name":"aerzteblatt.de","domain":"aerzteblatt.de","outlet":{"wikidata":"Q1206153","name":"Deutsches Ärzteblatt","type":"magazine","country":"DE","designations":["academic journal","apc-free journal","medical journal","open-access journal","scientific journal","trade magazine"]}},"via":"kite-aerzteblatt-de-f25596","topics":["medicine"],"entities":[{"id":"Q16831645","name":"Fresenius","type":"org"},{"id":"Q98344859","name":"mAbxience","type":"org"}],"mentions":2,"story":"st_5kaygdt26f7f7fzh4uma","category":"economy-business","category_p":0.6,"sentiment":"positive","tone":0.02,"political":0.04},{"id":"n_tcwmix4qqkjzbmejjzvq","seq":1097733,"kind":"article","title":"Bis zu 750 Millionen: Fresenius kauft Biopharma-Tochter ganz","title_en":"Up to 750 million: Fresenius buys biopharma subsidiary entirely","url":"https://www.main-echo.de/8793180","published":"2026-10-01T09:23:32Z","seen":"2026-10-01T09:23:32Z","lang":"de","country":"DE","source":{"id":"kite-main-echo-de-374725","name":"main-echo.de","domain":"main-echo.de","outlet":{"wikidata":"Q1430187","name":"Main-Echo","type":"magazine","designations":["organization","periodical"]}},"via":"kite-main-echo-de-374725","topics":["hesse"],"entities":[{"id":"Q16831645","name":"Fresenius","type":"org"}],"story":"st_phj4muukmesa6mdsanuq","category":"economy-business","category_p":0.88,"sentiment":"positive","tone":0.44,"political":0.03},{"id":"n_iovmacel5w7qwzxbxt7q","seq":1079911,"kind":"article","title":"Pharma: Bis zu 750 Millionen: Fresenius kauft Biopharma-Tochter ganz","title_en":"Pharma: Up to 750 million: Fresenius buys Biopharma subsidiary entirely","url":"https://www.tagesspiegel.de/wirtschaft/dpa-pharma-bis-zu-750-millionen-fresenius-kauft-biopharma-tochter-ganz-16114271.html","summary":"Der Medizin- und Klinikkonzern übernimmt für viel Geld seine Biopharma-Tochter mAbxience komplett und stärkt damit ein wichtiges Geschäft. Für 50 Millionen davon gibt es aber eine Bedingung.","published":"2026-10-01T07:46:26Z","seen":"2026-10-01T07:52:56Z","lang":"de","country":"DE","source":{"id":"kite-tagesspiegel-de-b20d44","name":"tagesspiegel.de","domain":"tagesspiegel.de","outlet":{"wikidata":"Q10189","name":"Tagesspiegel","type":"newspaper","country":"DE","designations":["daily newspaper"]}},"via":"kite-tagesspiegel-de-b20d44","topics":["berlin","wirtschaft"],"entities":[{"id":"Q16831645","name":"Fresenius","type":"org"}],"image":"https://www.tagesspiegel.de/images/16114270/alternates/BASE_4_3_W220/1790840787000/fresenius-konzernzentrale-in-bad-homburg.jpeg","mentions":2,"story":"st_phj4muukmesa6mdsanuq","category":"economy-business","category_p":0.87,"sentiment":"positive","tone":0.39,"political":0.03},{"id":"n_bvjff4tjbsln5qcgsbnq","seq":1057948,"kind":"article","title":"Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion","url":"http://www.prnewswire.com/news-releases/fresenius-completes-acquisition-of-mabxience-creating-a-stronger-platform-for-future-portfolio-expansion-302895070.html","published":"2026-10-01T05:20:34Z","seen":"2026-10-01T05:20:34Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","business","science"],"authors":["mAbxience"],"entities":[{"id":"Q16831645","name":"Fresenius","type":"org"},{"id":"Q98344859","name":"mAbxience","type":"org"}],"story":"st_bvjff4tjbsln5qcgsbnq","category":"economy-business","category_p":0.91,"sentiment":"positive","tone":0.85,"political":0.01},{"id":"n_lzi36sq3p3cs26urxvnq","seq":699919,"kind":"article","title":"Fresenius & NHS Partner on UK-First Net-Zero Dialysis Centre","url":"https://healthcare-digital.com/news/fresenius-nhs-partner-on-uk-first-net-zero-dialysis-centre","published":"2026-09-29T14:53:27Z","seen":"2026-09-29T14:53:27Z","lang":"en","source":{"id":"healthcare-digital.com","name":"healthcare-digital.com","domain":"healthcare-digital.com"},"via":"gdelt-gkg-english","topics":["economy","education","business","health"],"entities":[{"id":"Q16831645","name":"Fresenius","type":"org"},{"id":"Q918396","name":"National Health Service","type":"org"}],"story":"st_lzi36sq3p3cs26urxvnq","category":"health","category_p":0.35,"category2":"economy-business","sentiment":"positive","tone":0.63,"political":0.04},{"id":"n_dpxcdtcp6q3u7f2khiwq","seq":644227,"kind":"article","title":"Vom FBI bis zu Ticketmaster und Fresenius: Die Spur der Hackergruppe ShinyHunters","title_en":"From the FBI to Ticketmaster and Fresenius: The trail of the hacker group ShinyHunters","url":"https://www.tagesspiegel.de/internationales/vom-fbi-bis-zu-ticketmaster-und-fresenius-die-spur-der-hackergruppe-shinyhunters-16104925.html","summary":"Die international agierende Hackergruppe ShinyHunters behauptet, beim FBI persönliche Daten von Tausenden Beschäftigten erbeutet zu haben. Was über die Täter bekannt ist.","published":"2026-09-29T10:05:56Z","seen":"2026-09-29T10:48:12Z","lang":"de","country":"DE","source":{"id":"kite-tagesspiegel-de-b20d44","name":"tagesspiegel.de","domain":"tagesspiegel.de","outlet":{"wikidata":"Q10189","name":"Tagesspiegel","type":"newspaper","country":"DE","designations":["daily newspaper"]}},"via":"kite-tagesspiegel-de-b20d44","topics":["berlin","internationales"],"entities":[{"id":"Q8333","name":"Federal Bureau of Investigation","type":"org"},{"id":"Q2609162","name":"Ticketmaster","type":"org"},{"id":"Q16831645","name":"Fresenius","type":"org"},{"id":"Q105393930","name":"ShinyHunters","type":"org"}],"image":"https://www.tagesspiegel.de/images/16105313/alternates/BASE_4_3_W220/1790674661000/illustrative-the-logo-of-the-federal-bureau-of-investigation-and-the-shinyhunters-website-on-the-dark-web-where-the-h.jpeg","mentions":2,"story":"st_dpxcdtcp6q3u7f2khiwq","category":"science-technology","category_p":0.4,"category2":"arts-culture-entertainment","sentiment":"neutral","tone":-0.05,"political":0.16}]}